US America Pouchitis Treatment Market Research Report Information By Treatment (Antibiotics (Ciprofloxacin, Metronidazole, Rifaximin), Probiotics, and others (Budenoside, Immunosuppressive Therapy)), End Users (Hospitals & Clinics, Institutes) – Forecast till 2030

In North America, which includes the United States, there is a significant number of people dealing with pouchitis, and a lot of money is spent on healthcare. According to the Centres for Disease Control and Prevention, around 1.3% of adults in the U.S. were diagnosed with inflammatory bowel disease (IBD) in 2015. The number of cases of ulcerative colitis, one of the conditions leading to pouchitis, ranges from 37 to 246 cases per 100,000 people.

The market for treating pouchitis in the Americas, specifically North America, is growing. It's expected to reach USD 18.8 million by 2023, up from USD 9.79 million in 2016. This growth is anticipated to continue at a rate of 8.34% each year from 2017 to 2023. When we look at the ways pouchitis is treated, the use of antibiotics is quite common, making up 91.2% of the market share in 2016. The antibiotic segment is also expected to keep growing at a healthy rate of 8.65% annually from 2017 to 2023.

In terms of who is using these treatments, hospitals and clinics are the primary users, making up 67.3% of the market in 2016. This segment is projected to continue growing at a rate of 8.54% each year from 2017 to 2023. So, not only is the number of pouchitis cases increasing in North America, but the market for treating this condition is also expanding, with antibiotics being a key part of the treatment and hospitals and clinics being the main users of these treatments.